YQYing Qu

Ying Qu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ying Qu has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of Different Strategies for ROI-Based Measurements of Proton Density Fat Fraction in NAFLD

    by Jingyi Lu, Youchen Xia, Rong Mu, Qian Luo, Lei Zhang, Kouyun Zhu, Xiaobo Cai, LunGen Lu, Ying Qu

    Aims: MRI-PDFF is a promising non-invasive method of quantifying liver fat. This study assessed the reproducibility and repeatability of MRI-based PDFF in NAFLD patients, the consistency between different ROI sampling strategies, as well as the learning time burden of PDFF measurement. Methods: 90 NAFLD patients and 30 healthy people were enrolled in this cross-sectional study. Three reviewers measured liver PDFF by circling ROIs in four segments, nine Couinaud segments, and a random place on the PDFF map, respectively. Bland-Altman analysis and ICC were used to evaluate the inter- and intra-reviewer agreements for liver PDFF. Results: Circling ROIs within nine Couinaud segments had the narrowest limit of agreement (LOA) for PDFF measurements. For all 120 subjects, the intra-reviewer agreement had mean LOA of ±0.9% for three strategies, while the inter-reviewer agreement had mean LOA of ± 0.93%. We additionally determined that inter-group consistency increased with decreasing liver fat content for all ROI-circling strategies. The CUSUM learning curve shows that after 17 cases, beginners circled the ROIs more efficiently and accurately. Conclusions: Researchers and clinicians can circling one random ROI for mass screening of patients with NAFLD. We suggest training beginners perform at least 17 PDFF maps to acquire reliable data.

  • Diagnostic value of FibroTouch in identifying hepatic steatosis in NAFLD with MRI‐PDFF as the reference standard

    by Rong Mu, You Chen Xia, Kou Yun Zhu, Jing Yi Lu, Qian Luo, Lei Zhang, Ren Kun Lin, Xiao Bo Cai, Ying Qu, Lun Gen Lu

    Objective: To estimate the performance of the FibroTouch-based ultrasound attenuation parameter (UAP) for assessing hepatic steatosis in nonalcoholic fatty liver disease (NAFLD), with magnetic resonance imaging proton density fat fraction (MRI-PDFF) as the reference standard.Methods: This prospective, cross-sectional study included 275 individuals in the training group and 110 individuals in the validation group, all of whom completed a standardized research visit, laboratory tests, MRI-PDFF, and UAP measurements over 1 month. Pearson correlation coefficient and Bland-Altman analysis were used to assess the agreement between UAP and MRI-PDFF for the detection of hepatic steatosis. The diagnostic value of UAP was evaluated by the area under the receiver operating characteristic (ROC) curve (AUROC). Confounding factors to UAP performance were identified by ROC curves and regression analyses.Results: The AUROC of UAP for detecting MRI-PDFF at >= 5%, >= 10%, and >= 20% were 0.95 (95% confidence interval [CI] 0.92-0.97), 0.86 (95% CI 0.81-0.90), and 0.90 (95% CI 0.86-0.93), respectively, and their optimal thresholds were 259, 274, and 295 dB/m, respectively. The UAP measurements had higher diagnostic accuracy in participants with lower waist circumference (<= 90 cm for men and <= 80 cm for women) compared to those with higher waist circumference (AUROC values: 0.97 vs 0.84, P < 0.05). Bland-Altman analysis showed good agreement between UAP and MRI-PDFF (bias 0.00021). According to established regression analyses, hepatic steatosis could be accurately diagnosed using UAP estimation.Conclusions: FibroTouch-UAP has a high diagnostic potential for hepatic steatosis in NAFLD patients and helps clinical assessment and monitoring.


  • Open Access

    Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

    by Ying Qu, Yan-Yan Song, Cheng-Wei Chen, Qing-Chun Fu, Jun-Ping Shi, Yun Xu, Qing Xie, Yong-Feng Yang, Yong-Jian Zhou, Liang-Ping Li, et al.

    INTRODUCTION: To evaluate the diagnostic performance of ultrasound attenuation parameter (UAP) and liver stiffness measurement (LSM) by FibroTouch for diagnosis of hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). METHODS: We recruited 237 patients undergoing FibroTouch and liver biopsy within 2 weeks. The pathological findings of liver biopsy were scored by Nonalcoholic Steatohepatitis Clinical Research Network, and the diagnostic accuracy of UAP for steatosis and LSM for fibrosis was evaluated by area under the receiver operating characteristic curve (AUROC). The impacts of histological parameters on UAP and LSM were analyzed, and diagnostic performance of FibroTouch UAP and LSM was compared with other noninvasive biomarkers. RESULTS: The success rate of FibroTouch examination was 96.51%. The AUROC of UAP for diagnosis of steatosis ≥S1, ≥S2, and S3 was 0.88, 0.93, and 0.88, and the cutoff values were 244, 269, and 296 dB/m, respectively. The AUROC of LSM for the diagnosis of fibrosis stages ≥F2, ≥F3, and F4 was 0.71, 0.71, and 0.77, and the cutoff values were 9.4, 9.4, and 11 kPa, respectively. Multiple regression analysis showed that LSM was positively correlated with degree of fibrosis and NAFLD activity score. UAP was positively correlated with liver steatosis. The diagnostic performance of UAP for steatosis was significantly superior to that of the hepatic steatosis index. DISCUSSION: FibroTouch has a low failure rate with moderate to high diagnostic performance for discriminating the steatosis degree and fibrosis stage and is suitable for clinical evaluation and monitoring of patients with NAFLD.


  • Open Access

    Prediction of hepatic necroinflammatory activity in patients with chronic hepatitis B by a simple noninvasive model

    by Fei-Fei Shen, Yan Wang, Yi-Fei Wang, Rui-Dan Zheng, Jian-Chun Xian, Jun-Ping Shi, Ying Qu, Yu-Wei Dong, Ming-Yi Xu, Lun-Gen Lu

    A model was constructed using clinical and serum variables to discriminate between chronic hepatitis B (CHB) patients with and without significant necroinflammatory activity (score 4–18 vs. score 0–3). Consecutive CHB patients who underwent liver biopsy were divided into two sequential groups: a training group (n = 401) and a validation group (n = 401). Multivariate analysis identified alanine aminotransferase, γ-glutamyltransferase, prothrombin time and albumin as independent predictors of necroinflammatory activity. The area under the receiver operating characteristic curve was 0.826 for the training group and 0.847 for the validation group. Using a cut-off score of H ≤ 0.375, significant necroinflammatory activity (score 4–18) was excluded with high accuracy [78.2% negative predictive value (NPV), 72% positive predictive value (PPV), and 90.8% sensitivity] in 238 (59.4%) of 401 patients in the training group and with the same certainty (88.1% NPV, 61.2% PPV, and 95.1% sensitivity) among 204 (50.9%) of 401 patients in the validation group. Similarly, applying a cut-off score of H > 0.720, significant necroinflammatory activity was correctly identified with high accuracy (90.8% PPV, 57.7% NPV, and 92.0% specificity) in 150 (37.4%) of 401 patients in the training group and with the same certainty (91.8% PPV, 64.6% NPV, and 95.4% specificity) in 188 (46.9%) of 401 patients in the validation group. A predictive model based on easily accessible variables identified CHB patients with and without significant necroinflammatory activity with a high degree of accuracy. This model may decrease the need for liver biopsy for necroinflammatory activity grading in 72.1% of CHB patients.


  • [Predication analysis of microarray data to determine altered gene profiles in liver carcinoma related to HBV-related cirrhosis].

    by Jianwei Liu, Qingqing Zhang, Zhenghong Li, Qidi Zhang, Ying Qu, Lungen Lu, Mingyi Xu

    To investigate whether gene expression profiles can be used to determine risk genes and predict HBV-related cirrhosis progression to liver carcinoma using Significance Analysis of Microarray (SAM) and Prediction Analysis of Microarray (PAM) methods. The Affymetrix GeneChip was used to establish the gene expression profiles of liver tissues from 15 patients with chronic hepatitis B and cirrhosis or hepatocellular carcinoma (HCC). Differentially expressed genes (fold-change more than 2; P value less than 0.01) were selected by GeneSpring GX software. Risk genes related to cirrhosis and liver carcinoma were generated by SAM and PAM methods. Real-time PCR was used to verify the expression of risk genes in the liver tissues. Samples were clustered into the cirrhosis subgroup (n =15) or the HCC subgroup (n =15). A total of 497 differentially expressed genes were identified, SAM identified 162 significant genes, including 18 up-regulated genes and 144 down-regulated genes (fold-change:-1.46 to 1.28). PAM identified 22 genes with a "poor risk signature" (defined with a threshold of 5.5), which were associated with classifying cirrhosis and liver carcinoma; of these risk genes, 4 were down-regulated and 18 were up-regulated in the HCC group compared to the cirrhosis group (fold-change: 2.038 to 7.897, P value less than 0.01). The correction of classification was more than 80% . FOXP1, SPINK1 and KCNJ16 were verified by real-time PCR as differently expressed in the two subgroups (P value =0.011, 0.002 and 0.004, respectively). The altered gene profiles of carcinogenesis in HBV-related cirrhosis involves hundreds of genes. The combination of three "poor risk genes" may represent potential targets for diagnosis and prediction of liver carcinoma progression.


  • Open Access

    Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B

    by Ming-Yi Xu, Xiao-Fang Jia, Ying Qu, Rui-Dan Zheng, Zheng-Hong Yuan, Hong-Lei Weng, Steven Dooley, Xing-Peng Wang, Li-Jun Zhang, Lun-Gen Lu

    Due to known limitations of liver biopsy, reliable non-invasive serum biomarkers for chronic liver diseases are needed. We performed serum peptidomics for such investigation in compensated chronic hepatitis B (CHB) patients. Liquid chromatography combined with tandem mass spectrometry (LC-MS/MS) was used to identify differentially expressed peptides in sera from 40 CHB patients (20 with S0G0-S1G1 and 20 with S3G3-S4G4). Ion pair quantification from differentially expressed peptides in a validation set of sera from 86 CHB patients was done with multiple reaction monitoring (MRM). 21 differentially represented peptide peaks were found through LC-MS/MS. Ion pairs generated from eleven of these peptides (m/z < 800) were quantified by MRM. Summed peak area ratios of 6 ion pairs from peptide m/z 520.3 (176.1, 353.7, 459.8, 503.3, 351.3, 593.1), which was identified as dihydroxyacetone kinase (DAK) fragment, decreased from mild to advanced stages of fibrosis or inflammation. Area Under Receiver Operating Characteristic Curves (AUROCs) of five ion models discriminating fibrosis degrees were 0.871 ~ 0.915 (S2-4 versus S0-1) and 0.804 ~ 0.924 (S3-4 versus S0-2). AUROCs discriminating inflammation grades were 0.840 ~ 0.902 (G2-4 versus G0-1) and 0.787 ~ 0.888 (G3-4 versus G0-2). The diagnostic power of these models provides improved sensitivity and specificity for predicting disease progression as compared to aspartate aminotransferase to platelet ratio index (APRI), FIB-4, Forn's index and serum DAK protein. The peptide fragment (m/z 520.3) of DAK is a promising biomarker to guide timing of antiviral treatment and to avoid liver biopsy in compensated CHB patients.


  • 18?-glycyrrhizin ameliorates oxidative stress in rats with CCl4-induced liver fibrosis

    by Tian-Peng Ding, Ying Qu, Lun-Gen Lu, Gen-Lin Shi, Ruo-Fei Wang

    目的: 探讨18α甘草酸(18α glycyrrhizin, 18α-GL)对四氯化碳(carbon tetrachloride, CCl4)诱导的大鼠肝纤维化的作用. 方法: 建立动物模型: 采用40% CCl4皮下注射方法建立肝纤维化模型. 动物分为对照组、肝纤维化模型组和18α-GL干预组(高、中、低剂量). 8 wk后, 做HE和Masson染色观察病理情况, 并检测肝脏组织丙二醛(malondialdehyde, MDA)、4-羟基壬烯酸(hydroxynonnenal, HNE)含量及超氧化物酶(superoxide dismutase, SOD)和谷胱甘肽过氧化物酶(glutathione peroxidase, GSH-PX)活力. 结果: 18α-GL能够显著改善纤维化大鼠肝脏组织病理学变化, 发现在模型组中MDA和HNE含量显著升高(均P<0.05), 而18α-GL能够提高肝脏组织中SOD和GSH-PX活力(均P<0.05), 抑制脂质过氧化物MDA和HNE表达. 结论: 18α-GL能够改善肝纤维化大鼠病理, 具有抗氧化和抗纤维化作用.

  • [Waist-to-hip ratio is a superior predictor for non-alcoholic simple fatty liver].

    by Li Jiang, Xue-Wan Chen, Rui-Dan Zheng, Jie Chen, Jia-Rong Meng, Ming-Yi Xu, Ying Qu, Lun-Gen Lu